Overview

Study of an Investigational Drug, ASP3026, in Patients With Advanced Malignancies (Solid Tumors and B-Cell Lymphoma)

Status:
Completed

Trial end date:
2016-03-01

Target enrollment:

Participant gender:

Summary

This study is to evaluate the safety and anti-tumor activity of ASP3026 in patients with advanced malignancies (solid tumors and B-cell lymphoma).

Phase:

Phase 1

Details

Lead Sponsor:

Astellas Pharma Inc